291 results about "Cerebral arterial thrombosis" patented technology

The invention discloses HGG (Human Gammaglobulin) polypeptide in combination with the tissue specificity of cerebral arterial thrombosis. The invention relates to a method for obtaining the polypeptide. The method comprises the following steps: carrying out in-vivo selection of a mouse MCAO (Middle Cerebral Artery Occlusion) cerebral arterial thrombosis model by adopting an in-vivo phage display peptide library screening technology so as to obtain phage clones in combination with cerebral arterial thrombosis tissue; and randomly selecting the plurality of phage clones to sequence, and authenticating the in-vivo combination specificity of HGG peptide and coded phage clones HGG-M13 thereof. The invention further relates to application of the polypeptide in preparation of a high-sensitivity imaging molecular probe and a targeting delivery neuroprotective drug for cerebral stroke. The polypeptide can be synthesized through an artificial method; the polypeptide is low in molecular weight, high in activity and penetrating power, good in specificity and low in toxicity, and has good tissue targeting of cerebral arterial thrombosis in vivo; and therefore, the polypeptide is applicable to serving as a carrier of the high-sensitivity imaging molecular probe and the targeting delivery neuroprotective drug.

The invention discloses a cerebral arterial thrombosis targeted red cell membrane bionic intellectual drug carrier. The drug carrier is prepared from a nanometer vesica, a red cell membrane and cerebral ischemia homing peptide SHp, wherein the nanometer vesica serves as an inner core and is used for packing NR2B9C, the red cell membrane is arranged on the outer layer, the cerebral ischemia homing peptide SHp is modified on the surface of the cerebral ischemia, and the wrapping fusion between the nanometer vesica serving as the inner core and the red cell membrane on the outer layer is achieved through an ultrasonic fusion technique. The nanometer vesica is prepared from amphiphilic block copolymer (PHB-Dextran) serving as a carrier material, the amphiphilic block copolymer is prepared from hydrophobic borate which is grafted to a hydrophilic glucan framework, the nanometer vesica is used for wrapping a neuroprotective agent NR2B9C, and the amino acid sequence of the neuroprotective agent NR2B9C is KLSSIESDV. The carrier has the characteristics of having biocompatibility, prolonging circulation time in the body and initiatively targeting the focus position of the cerebral arterial thrombosis.

The invention discloses the use of an agent for detecting microRNA in exosomes in the preparation of a product for judging the presence and / or degree of cerebral ischemic injury, and relates to a method for early discrimination of a subject suffering from cardiogenic ischemic stroke and non-cardiogenic ischemic stroke. The method uses the exosomes in high-molecular polymer precipitate serum and areal-time fluorescence quantitative PCR technology, and experimental results show that the specificity and sensitivity of miR-155-5p and miR-93-5p are significantly higher than existing protein markers. Meanwhile, miR-133a-3p and miR-208a-3p expression of the exosomes of patients with cardiogenic ischemic stroke is significantly higher compared with patients with non-cardiogenic ischemic stroke under the condition of no significant changes in the serum miR-133a-3p and miR-208a-3p at the early stage so that the agent can be used as a marker to distinguish the cardiogenic ischemic stroke and thenon-cardiogenic ischemic stroke.

The invention relates to the technical field of medical auxiliary recognition and relates to a focus recognition method for ischemic stroke magnetic resonance images. The method comprises an image input step, a DWI image processing step, an ASL image processing step, an infusion calculation step, a low perfusion calculation step, a DWI three-dimensional reconstruction step, an ASL three-dimensional reconstruction step, and an ischemia semi-dark zone identification step and the like. In the DWI image processing step and the ASL image processing step, a morphological method is adopted to enhance the characteristics of the image. Focus segmentation and direct volume calculation are realized based on a segmentation method of an adaptive threshold value. Ischemia semi-dark band recognition is realized through an image registration algorithm, and then a Mismatch value is calculated. The cerebral arterial thrombosis lesion position can be accurately recognized, a specific lesion volume value is provided, three-dimensional visual data display is provided, an accurate reference basis is provided for diagnosis and treatment of doctors, and clinical decision making of the doctors is assisted.

The invention discloses lncRNA for diagnosing cerebral arterial thrombosis. The lncRNA is LOC105376505. According to the lncRNA for diagnosing cerebral arterial thrombosis, the LOC105376505 gene is related to occurrence and development of cerebral arterial thrombosis, expression in cerebral arterial thrombosis patients is reduced, and researching of pathogenesis of cerebral arterial thrombosis is further enriched.

The invention discloses a multi-mode nuclear magnetic image cerebral arterial thrombosis lesion segmentation method based on a convolutional neural network. The method comprises the steps of designinga deep convolutional neural network 1 based on an original framework of a 3D U-Net network; basic modules based on a 3 * 3 * 3 convolution layer and a batch standardization layer; a 3D deformable convolution module based on a 3 * 3 * 3 convolution layer and trilinear interpolation; a cascade deformation module based on the 3D deformable convolution module and the basic module; constructing a deepconvolutional neural network 2 based on the 3D U-Net network and the cascaded deformation module; inputting the processed data into a neural network 1 for pre-training; assigning a weight obtained bypre-training to a neural network 2 for training; and verifying the segmentation effect on the test set of the pixel-level label. The invention provides an automatic labeling method for ischemic stroke lesion segmentation, so that the cost of labeling data is greatly reduced, the engineering operability is enhanced to a certain extent, and doctors are assisted in clinical diagnosis of ischemic stroke patients.

The invention discloses application of lncRNA (long non-coding ribonucleic acid) to diagnosing cerebral ischemic stroke. The lncRNA is LOC101929707. The application has the advantages that correlation between LOC101929707 genes and occurrence and development of the cerebral ischemic stroke is discovered, and accordingly the LOC101929707 can be used as a possible detection target to be applied to early diagnosing the cerebral ischemic stroke on the basis of the correlation.

The invention discloses a miRNA marker. The miRNA marker is miRNA-4252. Whether a patient suffers from cerebral arterial thrombosis or not can be diagnosed by detecting the expression level of the miRNA-4252. An experiment shows that a cerebral arterial thrombosis patient and a healthy person can be effectively differentiated through the miRNA-4252. On the basis, the miRNA-4252 can be used for preparing a product for diagnosing the cerebral arterial thrombosis. By means of the cerebral-arterial-thrombosis miRNA marker, the sensitivity and the specificity of diagnosing of the cerebral arterial thrombosis can be greatly improved, and early diagnosis of the cerebral arterial thrombosis is achieved.

The invention belongs to the technical field of medicines, and relates to a novel method for preparing shiny-leaved yellowhorn total saponins from shiny-leaved yellowhorn and an application of the shiny-leaved yellowhorn total saponins. According to the method, a coarse extract of the shiny-leaved yellowhorn is directly separated and purified by a macroporous resin method to obtain shiny-leaved yellowhorn total saponins; the yield of the total saponins is over 5 percent, and the content of the total saponins in a product is over 60 percent and far higher than that in products prepared by other processes. The prepared shiny-leaved yellowhorn total saponins can be applied to preparation of medicines or health-care products for preventing and treating memory deterioration, hypophrenia and cranial nerve injury caused by neurodegenerative diseases and acute and chronic cerebral injury diseases, and can be used for treating cerebral diseases caused by alzheimer disease, acute disease and subacute stage of cerebral arterial thrombosis, vascular dementia and other ischemia and hypoxia of neurodegenerative diseases and acute and chronic cerebral injury diseases.

The invention discloses an application of a photochemically-induced cerebral arterial thrombosis model for zebra fish. The cerebrum tissue is taken as an identification index of cerebral arterial thrombosis model for zebra fish. The principle of forming photochemically-induced thrombus is adopted. A rose-bengal solution is injected to abdominal cavities of zebra fish. Therefore, complete local infarction in cortex areas of zebra fish is caused by illumination within short time. Accordingly, an in vivo animal model is established. In the model, blood coagulation is caused by damaging vascular endothelial cells due to singlet oxygen released by the rose-bengal solution under light irradiation. The pathological process of cerebral arterial thrombosis is effectively simulated. According to anexperiment result of an observational index, the cerebrum area tissue of zebra fish has evident loose and infarct phenomena. Swimming behaviors of dysneuria such as whirling and standing upright occurto zebra fish. The method is simple and high in success rate and convenient to promote. Damage sensitivity of cerebrum tissue is high and repeatability is good. The photochemically-induced cerebral arterial thrombosis model for zebra fish can act as a practical tool index for screening medicine, for blood vessel protection after cerebral infarction and thrombolytic therapy.

The invention provides application of peroxidase Prdx1 (peroxiredoxin-1) to preparation of a drug for preventing and treating cerebral injury diseases based on cerebral arterial thrombosis, vascular dementia and other cerebrovascular diseases. According to the invention, a Prdx1 gene-carrying overexpression plasmid and a recombinant lentiviral vector are established, cell and whole animal level tests prove that the Prdx1 is capable of effectively reversing the ischemic injury of vascular endothelial cells, protecting a BBB (Blood Brain Barrier) and relieving nerve function deficits caused by cerebral microcirculatory disturbance, and therefore, the effect of preventing and treating the cerebrovascular diseases is achieved. The Prdx1 gene lentiviral vector provided by the invention is expected to become an important way for developing the drug for treating the cerebrovascular diseases, and experimental basis is provided to the application of the Prdx1 gene to gene therapy of the cerebrovascular diseases.

The invention relates to the medical field, discloses applications of racemes of pinocembrin, racemes of pinocembrin salt, racemes of pinocembrin precursors or racemes of pinocembrin hydrate in preparation of medicals for preventing and treating cerebral apoplexy, and further discloses the application of racemes of pinocembrin in prevention and treatment of acute ischemic stroke.

The invention relates to preparation and applications of a biologically camouflaged targeting nano drug delivering system for treating ischemic cerebral stroke. The nano drug delivering system is compose of a drug, an inner core drug carrier, a biologically camouflaging shell, and a target finding material, wherein the drug is bilobalide B, the inner core drug carrier is recombinant high density lipoprotein, a drug is physically embedded into the drug carrier to form a drug loaded inner core; the biologically camouflaging shell is a blood platelet membrane, the drug loaded inner core is embedded in the blood platelet membrane in a co-extrusion mode to form a biomimetic drug loaded nano particle; the target finding material is a cerebral ischemia targeting peptide (CITP), and the CITP is used to modify the surface of the biomimetic drug loaded nano particle to form the biologically camouflaged targeting nano drug delivering system. Recombinant high density lipoprotein is used to wrap bilobalide B to form the drug loaded inner core, a blood platelet membrane and a blood platelet with a CITP modified surface are taken as the biomimetic shells to construct a nano particle for treatingischemic cerebral stroke, the circulation time of the nano particle in human body is prolonged, and the nano particle has a good targeting performance.

The invention discloses aryl substituted piperazine carbonyl derivative as well as a preparation method and application thereof. The aryl substituted piperazine carbonyl derivative is free alkali or salt of a compound adopting a general formula (I) shown in the Specification, wherein the salt is one of hydrochloride, hydrobromide, sulfate, trifluoroacetate, tartrate, lactate or mesylate; Ar independently represents aryl, substituted heterocyclic ring or substituted aryl; R1 independently represents (-O-CH2-) or (-CH=CH-); R2 and R3 can be the same or different, and respectively and independently represents H, halogen, alkyl, halogen substituted alkyl, nitro, amino, nitrile group, hydroxyl, alkoxy, aryl alkoxy, heterocyclic ring alkoxy, aryl, substituted heterocyclic ring or substituted aryl. The aryl substituted piperazine carbonyl derivative can be applied to the preparation of drugs for treating cerebral arterial thrombosis.

The invention discloses a multi-modal cerebral apoplexy lesion segmentation method based on small sample learning, and the method comprises the steps: obtaining an original brain training sample which comprises a multi-modal CT medical image and an annotation image, and the original training sample comprises CT, CBF, CBV, MTT, TMax and ischemic cerebral apoplexy lesion tags; the method comprises the following steps: preprocessing a multi-modal medical image, carrying out image augmentation through modes of image deformation, image scaling, generative adversarial and the like, and expanding a small sample image data set; registering the multi-modal image after data augmentation, taking a reference image as a CT image, and performing pixel-level fusion on the multi-modal image after registration; and the fused multi-modal image data is transmitted to a segmentation network constructed based on Transform to carry out image segmentation. The invention further discloses a system using the method. According to the method, the influence on a medical image data segmentation task caused by insufficient data samples is improved, more focus image information is obtained through multi-modal image fusion, and the accuracy of image segmentation is improved.

The invention discloses a cerebral stroke CT image segmentation method, which comprises the following steps of: overturning an ischemic cerebral stroke CT image, and preprocessing an original CT image and the overturned CT image; constructing twin multistage encoders, calculating the feature difference of each stage of the two encoders by a calculation module, and fusing features by using a multistage feature fusion module; constructing a shared decoder; designing a joint loss function, and training an optimal segmentation model on the training set; and finally, performing ischemic cerebral apoplexy infarction segmentation on a test set of an unknown segmentation label by using the trained segmentation model. According to the invention, the feature difference calculation module is used to calculate the feature difference of each level of two encoders, and the multi-level feature fusion module is used to fuse the global and local features; the infarction in the CT image can be accurately segmented, and technical support and reference are provided for improving the ischemic stroke diagnosis efficiency and accuracy and reducing the fatality rate and disability rate.

The invention discloses IncRNA markers of cerebral arterial thrombosis. The IncRNA markers are LINC00189 and LOC105376014, wherein the expression of the LINC00189 is up-regulated in a patient with cerebral arterial thrombosis, and the expression of the LOC105376014 is down-regulated in the patient with cerebral arterial thrombosis. The IncRNA markers can be used for early diagnosis of cerebral arterial thrombosis and has relatively high sensitivity and specificity.

The invention discloses a compound of a structure shown by a formula I and a pharmaceutically acceptable salt or solvent compound thereof, wherein R1, R2, R3 and R4 are respectively and independently selected from H, F, Cl, Br, CN, CF3, OH, NO2, NH2, substituted or non-substituted C1 to C6 alkyls, substituted or non-substituted C1 to C6 alkoxy, substituted or non-substituted C1 to C6 alkyl acyls or substituted or non-substituted C1 to C6 alkyl amido groups. The invention also discloses a preparation method of the pharmaceutically acceptable salt or solvent compound of the compound of the structure shown by the formula I and application of the compound to the preparation of medicines for preventing and treating cerebral arterial thrombosis. The formula I is shown in the description.

The invention belongs to the bio-pharmaceutical technical field and relates to a preparation method and application of a targeted nano delivery system for treatment of cerebral ischemia. In the invention, polyamide-amine (PAMAM) dendritic polymer is taken as the basic drug carrier, micromolecular T7 peptide is taken as the brain-targeted ligand, the T7 peptide and PAMAM are connected by polyethylene glycol (MAL-PEG-NHS) with bifunctional group and ultimately pharmaceutical molecules are entrapped by physical embedding to build a brain-targeted nano delivery system. The targeted nano delivery system for the cerebral ischemia prepared by the invention enters brains by endocytosis between the T7 peptide and surface receptors of blood brain barrier (BBB) to improve drugs' BBB transmittance, make the drugs be enriched at ischemic focus locations in a selective way, enhance drugs' bioavailability and targeting, and reinforce drugs' protection against focal cerebral ischemia reperfusion injury and has a broad application prospect in the treatment of cerebral arterial thrombosis.

The invention discloses indexes and a system for predicting prognosis of an acute ischemic stroke patient undergoing vascular recanalization treatment. The indexes comprise PAC variability and parameters thereof. Correlation analysis proves that the PAC variability and the parameters thereof are related to prognosis of cerebral arterial thrombosis patients. According to the research results, the invention develops the system and a method for predicting prognosis of the acute ischemic stroke patient undergoing vascular recanalization treatment, and provides a new strategy for clinical prediction of prognosis of the patients.

The invention belongs to the field of biotechnology and cerebral arterial thrombosis, and particularly relates to application of circular RNA circ-FoxO3 in preparation of products for preventing and treating cerebral arterial thrombosis. The circular RNA is highly conservative and has the same reverse shearing site in human-derived or mouse-derived species. The application proves that the circ-FoxO3 is highly expressed in cerebrovascular endothelial cells of a MCAO / R mouse and the cerebrovascular endothelial cell line subjected to OGD / R treatment; A certain effect of the circ-FoxO3 in the endothelial barrier treated by OGD / R is shown by knockdown or over-expression of the circFoxO3. The application of the circular RNA circ-FoxO3 provides a new thought for prevention of hemorrhagic transformation after acute ischemic stroke, and provides a new target for development of a neurovascular protective agent.

The invention relates to a medicine for preventing and treating ischemic stroke. In the mouse cerebral ischemia-reperfusion model, the compound of the present invention can significantly reduce the behavioral score, can significantly reduce the percentage of cerebral infarction / whole brain, and can significantly reduce the water content of ischemia-reperfusion damaged brain tissue, and relieve ischemia. The degree of lateral cerebral hemisphere edema can be used to prevent and treat ischemic stroke.

The invention relates to a substituted benzhydryl piperazine derivative and a preparation method and an application of the substituted benzhydryl piperazine derivative. The substituted benzhydryl piperazine derivative has a compound in structural formula (I): FORMULA. A part of compound provided by the invention is administrated preventively to prolong the survival time of mice suffering from acute cerebral ischemia so that the derivative has a certain neuroprotective effect of preventing cerebral ischemia. Thus, the compound provided by the invention can be used to prepare medicines for treating cerebral arterial thrombosis.

Provided are a substituted aryl oxygen ethylpiperazine derivative, a preparation method of the substituted aryl oxygen ethylpiperazine derivative and application of the substituted aryl oxygen ethylpiperazine derivative. A compound is free alkali or salt with a compound of a structure in a general formula (I), the salt is one of hydrochloride, hydrobromide, sulfate, trifluoroacetic acid salt, tartrate, lactate or mesylate, wherein an Ar independently stands for aryl groups, substituted heterocyclic rings or substituted aryl groups, an R1 and an R2 are same or different, and the R1 and the R2 independently stand for H, halogen, alkyl, halogen substituted alkyl, nitro, amino, nitrile groups, hydroxyl, alkoxy, aralkyl oxygroup, heterocyclic ring alkoxy, aryl group, the substituted heterocyclic rings or the substituted aryl groups respectively. The substituted aryl oxygen ethylpiperazine derivative is applied to preparation of cerebral arterial thrombosis therapeutic drugs.

The invention discloses a cerebral-arterial-thrombosis diagnosis marker. The marker is miRNA-4511. The miRNA-4511 is highly expressed in a cerebral arterial thrombosis patient, and whether a patient suffers from cerebral arterial thrombosis or not or whether a patient has the risk of suffering from the cerebral arterial thrombosis or not can be diagnosed by detecting the expression level of the miRNA-4511. On the basis, the miRNA-4511 can be used for preparing a product for diagnosing the cerebral arterial thrombosis. As the cerebral-arterial-thrombosis diagnosis marker is discovered, the specificity and the sensitivity of diagnosing of the cerebral arterial thrombosis can be improved, and early diagnosis of the disease is achieved.

The invention discloses a medicine for treating ischemic cerebral arterial thrombosis, of which the active component is Z-octadecyl-9-alkenyl-propylsulfamide being 80-250 mg / kg in effective dose. The medicine is used in an oral manner. The active component of the medicine is the Z-octadecyl-9-alkenyl-propylsulfamide so that the medicine has a significant effect of treating the ischemic cerebral arterial thrombosis, can improve neurological deficit of mice, can reduce cerebral infarction volume and can alleviate the degree of encephaledema.

The invention belongs to the technical field of stem cells and particularly relates to umbilical cord mesenchymal stem cells modified by NTF4 (neurotrophin 4) gene and a construction method and application thereof. The umbilical cord mesenchymal stem cells modified by NTF4 gene are provided herein and can overexpress NTF4 protein. The umbilical cord mesenchymal stem cells modified by NTF4 gene canreplace damaged nerve cells, can well express NTF4 protein to arrive at nerve cell protection and promote cell regeneration and restoration, can be a treatment carrier having great potential of targeting therapy for cerebral arterial thrombosis, and can gain enhanced action of hUC-MSCs so that powerful combination is achieved. Experimental results show that the umbilical cord mesenchymal stem cells modified by NTF4 gene can be applied to model rats with focal cerebral ischemia to effectively repair brain damage of the rats.

The invention discloses a novel pyridine methylamino phthalide compound (I) and pharmaceutically acceptable salts, a preparation method and a pharmaceutical composition thereof and application thereofin preparation of medicines for treating and / or preventing nervous system related diseases. The diseases include but are not limited to vascular dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, HIV related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, glaucoma, cerebral arterial thrombosis, cerebral hemorrhagic stroke, nerve injury causedby cerebral trauma and the like.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for cerebral arterial thrombosis. The composition is prepared from the following raw materials in parts by weight: 30 parts of rhodiola rosea, 30 parts of angelica sinensis, 25 parts of acanthopanax root, 25 parts of sculellaria barbata, 25 parts of semen cassiae, 23 parts of semen raphani, 20 parts of lumbricus, 20 parts of gynostemma pentaphylla, 20 parts of radices trichosanthis, 20 parts of ligusticum wallichii, 17 parts of rhizoma acori graminei, 17 parts of caulis spatholobi, 15 parts of astragalus membranaceus, 15 parts of folia perillae acutae, 15 parts of radix curcumae, 12 parts of radix aucklandiae, 10 parts of mulberry, 10 parts of herba epimedii, 10 parts of semen plantaginis, 9 parts of hiraute shiny bugleweed herb, 7 parts of cistanche deserticola, 5 parts of nux vomica and 5 parts of radix aconiti preparata, wherein the raw materials are combined and complemented with each other. The composition has a rapid effect on the cerebral arterial thrombosis, thereby being wide in application prospect.

The invention discloses a class of novel salicylamide compounds (I) and a pharmaceutically acceptable salt thereof, a preparation method and a pharmaceutical composition thereof, and applications of the novel salicylamide compounds (I) and the pharmaceutically acceptable salt thereof in preparation of drugs for treating and / or preventing nervous system related diseases, wherein the diseases include but are not limited to vascular dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, HIV related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, glaucoma, cerebral arterial thrombosis, cerebral hemorrhagic stroke, nerve injury caused by cerebral trauma and the like.